Background: Pre-exposure prophylaxis (PrEP) is highly efficacious for preventing HIV but has not yet been brought to scale among at-risk persons. In several clinical trials in urban areas, technology-based interventions have shown a positive impact on PrEP adherence. In rural and small-town areas in the United States, which often do not have geographically proximal access to PrEP providers, additional support may be needed. This may be particularly true for younger persons who are more likely to face multiple barriers to accessing PrEP services. Home-based care, accomplished through a tailored mobile phone app, specimen self-collection (SSC), and interactive video consultations, could increase both PrEP initiation and persistence in care.
Objective: The goal of this study is to assess the initiation and persistence in PrEP care for those randomized to a home-care intervention (electronic PrEP, ePrEP) relative to those assigned to the standard of care (control) condition. We will conduct additional assessments, including quantitative and qualitative analyses, to contextualize trial results and facilitate scale-up.
Methods: This 2-arm, randomized controlled trial will enroll young men who have sex with men (YMSM) aged between 18 and 24 years from rural areas of Georgia, Mississippi, and North Carolina. The trial will seek to recruit a diverse sample, targeting 50% participation among highly impacted groups of black or Latino men who have sex with men. Intervention participants will receive a study app that incorporates a messaging platform, a scheduling and milestone-based tracking system for PrEP care progress, electronic behavioral surveys, and interactive video consultations with a clinician. Complemented by SSC kits mailed to laboratories for standard PrEP-related monitoring, the ePrEP system will allow participants to access PrEP care without leaving their homes. YMSM randomized to the control condition will receive a listing of nearest local PrEP providers to receive standard PrEP care. Both groups will complete quarterly electronic surveys. The primary outcome, assessed at 6 and 12 months after randomization, will be the difference in the proportion of intervention versus control participants that achieve protective levels of the active metabolite of oral PrEP (tenofovir diphosphate in dried blood spots).
Results: Enrollment will begin in May 2019, with study completion in 2022.
Conclusions: This trial will determine whether home PrEP care provided through an app-based platform is an efficacious means of expanding access to PrEP care for a diverse group of YMSM in rural and small-town areas of the United States.
Trial Registration: ClinicalTrials.gov NCT03729570; https://clinicaltrials.gov/ct2/show/NCT03729570 (Archived by WebCite at http://www.webcitation.org/78RE2Qizf)
International Registered Report Identifier (IRRID): PRR1-10.2196/13982
Crowdfunding campaign to support this specific research
We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.
Suggested contribution levels: $20/$50/$100
Men who have sex with men (MSM) continue to account for the majority of new HIV diagnoses in the United States . HIV prevalence among MSM in rural counties is high, with many counties exceeding 15% prevalence [ ]. Oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) was approved by the US Food and Drug Administration (FDA) for HIV pre-exposure prophylaxis (PrEP) in 2012. Large-scale clinical and pragmatic trials of oral FTC/TDF demonstrated high efficacy and effectiveness in preventing sexual HIV acquisition when taken consistently [ - ], yet a national database of PrEP-prescribing clinics developed by the authors indicates a substantial lack of providers in rural areas [ ]. There are a number of rural areas in the United States in which residents live in PrEP deserts, with no nearby PrEP-prescribing clinics [ ]. An estimated 38,000 MSM eligible for PrEP would require a ≥2-hour round trip drive to their nearest clinic; over 100,000 would require ≥1-hour round trip drive to access PrEP services [ ].
Within the elevated risk group of MSM, black MSM and young MSM (YMSM) aged between 15 and 24 years bear disproportionate burdens of incident HIV infection  and represent priority populations for interventions. Several successful technology-based interventions have been shown in clinical trials to increase PrEP adherence [ , ], yet these efforts have been conducted predominately in urban areas. The premise for this study is that a tailored approach for rural YMSM, addressing known barriers of transportation, access to knowledgeable providers, and privacy, is likely to yield demonstrable improvements in initiation of PrEP and persistence in PrEP care.
The focus of this project is the delivery of home-based PrEP care. Such a strategy has the potential to quickly make PrEP services available to MSM in rural areas who currently lack access. Using a mobile phone app, participants assigned to the intervention may initiate PrEP and be retained in follow-up care without leaving their home. This will be achieved through the electronic PrEP (ePrEP) system that combines app-based surveys and screening tools, interactive video consultations, and home specimen self-collection (SSC).
The primary aim of this efficacy trial is to determine the impact of the ePrEP system on the levels of PrEP protection achieved by MSM interested in initiating PrEP in rural and small-town areas. The hypothesis is that a higher proportion of ePrEP intervention participants will achieve biomarker-determined protective levels of tenofovir diphosphate (TFV-DP) relative to those randomized to standard of care (control). Secondary aims include conducting additional assessments to contextualize trial results, including adjusted analyses of the primary outcome, as well as cost effectiveness and cost-utility analyses.
PrEP-naïve MSM will be recruited into the study, with black and Latino MSM to comprise half of all participants. Initial screening will be conducted online; eligible individuals will complete an electronic consent () and a baseline survey ( ), and then will receive an SSC kit to verify clinical appropriateness of oral FTC/TDF use. The home SSC kit will comprise supplies needed to produce microtube and dried blood spot (DBS) samples for central laboratory testing, detailed instructions, and directions for mailing specimens to the laboratory. MSM determined to be eligible, including clinical eligibility to receive oral FTC/TDF as PrEP, will be enrolled and randomized to either intervention or control conditions. Randomization, conducted using the study’s electronic data capture (EDC) system, will be stratified by study site to decrease the likelihood of type I error because of the expected association between covariates and the primary study outcome.
Those assigned to the intervention ePrEP condition (n=120) will have an app-based interactive video consultation with a site study clinician who will prescribe PrEP as indicated . At months 1, 3, 6, 9, and 12 postrandomization, participants complete virtual study visits that include app-based surveys, video consultations, and quarterly SSC for laboratory testing (per current practice guidelines) [ ]. Participants assigned to the control condition (n=120) will be referred to a publicly available website that geolocates the nearest PrEP provider, using PrEP Locator [ ]. All participants will mail-in self-collected DBSs for the determination of the primary outcome assessment of TFV-DP at month 12 postrandomization. All participants will also complete electronic surveys for secondary outcome assessment at baseline and months 3, 6, 9, and 12 postrandomization ( ).
Study Population and Recruitment
We will randomize 240 participants in Georgia, North Carolina, and Mississippi. Target recruitment is 50% among highly impacted groups of black or Latino MSM. To be eligible, a potential participant must (1) have been assigned male sex at birth, (2) be aged between 18 and 24 years, (3) live in a rural or small-town zip code based on the Centers for Disease Control and Prevention’s (CDC) urbanicity classifications , (4) provide informed consent, (5) be able to complete study consent and survey processes in English, (6) be willing to provide complete contact information (including 2 alternate contacts), (7) be able and willing to provide identification for verification, (8) own an iOS or Android mobile phone capable of running the study app, (9) be willing to use study-provided PrEP financial navigation services, (10) be willing to self-collect specimens, (11) be HIV-uninfected, as determined by laboratory testing using an antigen/antibody combination assay, (12) have a serum creatinine level that suggests creatinine clearance ≥60 mL/min, as determined by the Cockcroft-Gault equation, (13) be hepatitis B virus uninfected, as determined by laboratory testing, (14) have an indication for PrEP based on current guidance, including consideration of epidemic conditions [ ], and (15) be interested in and willing to take daily FTC/TDF. Potential participants are excluded from enrollment if they (1) are currently taking oral FTC/TDF as PrEP, (2) have a medical contraindication to the use of FTC/TDF, (3) have symptoms of acute HIV infection, (4) are currently enrolled in any HIV prevention trials, (5) have a self-reported acquired or inherited disorder preventing the normal clotting of blood, such as hemophilia, or (6) have insurance coverage through a closed network system in which study clinicians cannot prescribe. Individuals with signs of acute HIV infection who are HIV antigen/antibody negative may, upon the discretion of study clinicians based on additional laboratory testing and/or discussion with the participant, be determined to be eligible for the study. Due to the additional clinical follow-up needed for persons with hepatitis B infection, we excluded those testing positive from this telemedicine study.
Primary participant recruitment will be conducted using banner advertisements and brief electronic messages on geospatial networking apps and social media platforms. Our target of 50% recruitment of highly impacted groups will be sought through study advertisement placement and content strategies. Although the target is not a hard cap, we anticipate that we will be able to meet it based on past recruitment experience and will seek alternative recruitment strategies as needed. Recruitment, led by the Emory Center for AIDS Research, which has led similar work previously [- ], will target ads to nonurban zip codes that would indicate potential eligibility for the study. Secondary methods for recruiting participants, such as peer referral, will be used if needed.
Screening, Consent, and Enrollment Procedures
Individuals responding to electronic ads will be directed to a secure electronic platform to view a brief introductory statement, consent to be screened, and complete a brief eligibility screener. Screener-eligible participants will provide personal contact information and complete the full study consent by using mouse drag/touchscreen features to capture and document their signature. Study staff will review name, contact information, and other data, such as internet protocol address, for ineligible individuals to detect any instances of rescreening. Staff will call participants to answer any questions they might have about the study and to reassess screener eligibility. Eligible and consenting participants will download the study app on their personal mobile phone from an app store and create a personal, password-protected app account. Both intervention and control participants will use research-assessment components of the app (eg, access to the survey platform and reminders); however, only intervention participants will have access to the app components relevant to PrEP care. The baseline survey will be immediately available for completion in the app, and the staff will receive an automated notification to mail an SSC kit to the participant to determine study eligibility. Participants will be enrolled in the trial and assigned a randomization code, if they return the SSC kit and complete the required study surveys within 1 month and the laboratory test results indicate eligibility. If these activities are not completed within 1 month, participants will be asked to repeat the appropriate previous step. Throughout the consent and enrollment process, study staff will be available by email and by phone during study hours to answer participants’ questions. Study recruitment and retention activities will be conducted centrally by the staff at Emory University.
The ePrEP intervention, developed based on Andersen behavioral model adapted to HIV care (ABMH), is designed to ease the burden of initiating and maintaining PrEP care by providing home SSC kits and telemedicine through a custom-built app for patients and Web portal for clinicians.
ABMH explicitly incorporates the biomedical nature of the intervention and also directly addresses patient experiences in health care and lived environments [, ]. This multilevel model, with a focus on health care settings, describes how environmental and patient-level factors impact both retention in care and medication adherence ( ). ABMH informs the development of a number of intervention components, such as an app-based scheduler to lower barriers to making appointments, an app-based message portal to increase provider responsiveness, use of PrEP-experienced pharmacies to facilitate PrEP prescriptions, use of interactive video consultations with lesbian, gay, bisexual, transgender, queer-friendly clinicians to facilitate provider trust, and referral strategies to address predisposing factors such as substance abuse or mental health problems. The model informs intervention assessment plans, including selection of appropriate measures and construction of multivariate models to assess intervention performance.
Specimen Self-Collection Kit
To allow for laboratory testing for PrEP care and for the study outcome, ePrEP will use an SSC kit that has previously been pilot tested . Participants will receive a plain box via standard mail that includes video and written instructions, materials for each specimen to be collected, and a call-in help line. After specimen collection, participants will enclose them in a prepaid mailer to be sent directly to a study laboratory. On the basis of the results from the pilot assessment, we anticipate that most participants will be able to self-collect specimens. Our study laboratory will perform a visual assessment for the sufficiency of self-collected specimens based on the study requirements for quantity (eg, enough blood in a card spot) and quality (eg, properly sealed containers). For specimens determined to be insufficient or with indeterminate results, we will give participants an option of completing a second SSC or receiving a referral to a local health department or a commercial laboratory. Testing of all specimens will be performed at Clinical Laboratory Improvement Amendments–certified laboratories, with costs covered by the study. FDA-approved tests will be used for all tests used for PrEP care.
The study app, generically named eP to protect participant privacy on their mobile phones, will be the primary participant-facing component of the intervention. eP will be structured around a dashboard timeline () that visually depicts successful completion of past steps (green check marks), proximal future steps that require immediate action (activity buttons), and distal future steps needed for maintenance in ePrEP care (grey dots next to an anticipated future due date). The adaptive dashboard will refresh as tasks are completed. For instance, once an SSC is returned, scheduling of the next interactive video consultation will become available. An inbox screen (bottom navigation bar) will feature a variety of automated messages for required actions, reminders, and updates to facilitate the participant’s progress in ePrEP care. This messaging system also allows for custom messages to be sent to and from study staff and clinicians. A profile screen will allow participants to alter their personal information, such as changing their preferred pharmacy or home shipping address, and a PrEP kit screen will allow participants to track shipping status of their SSC.
To initiate PrEP care, electronic surveys embedded in the eP app will collect behavioral information recommended by current practice guidelines . Photo upload functionality will be used for the communication of documents such as those needed for financial navigation of access to PrEP, such as insurance- or employment-related documents required for assistance or copayment programs. Interactive video consultations with study clinicians will be scheduled by patients through an electronic calendaring function. Initiated in the dashboard, the consultations will be conducted on a secure, encrypted and Health Insurance Portability and Accountability Act (HIPAA)–compliant video platform within eP. A secure inbox text message system will increase access to and streamline communication with the clinical care team regarding questions such as medication side effects.
When participants initially download eP, they will only be able to access app information relevant to the overall research process. Once randomized, the intervention group will be able to see and use all eP components. A modified version of the app will be used by control participants, which includes only components applicable to research participation such as processes around the primary and secondary outcomes data collection. Both eP app versions will be hosted in a secure environment that uses Single Socket Layer technology for encryption of online information transfer. Access to all systems will require authentication through individual log-ins and passwords, and all data will be stored on secure and HIPAA-compliant servers.
Study staff and clinicians will manage participant interactions through website portals developed for the study that use a cloud platform to exchange data with the participant-facing eP app. Both administration and clinician platforms will share a number of key features, including automatic alerts when activity is required, such as a patient needing an additional reminder to schedule their video consultation. A secure text message platform will allow staff and clinicians to send messages to the participant’s eP inbox. The administrative portal will allow for tracking of the participant’s progress in completing research-related activities, including visualizations of each participant’s movement through milestones essential to successful study retention. The clinical portal will allow clinicians to view clinically relevant information for study participants, including lab results, self-reported sexual behaviors, and self-reported PrEP adherence and side effects. Clinicians will specify their available time slots for the interactive video consultations in an electronic calendaring function. The clinical portal will allow the collection of nuanced care information during consultations—general assessments, adherence assessments, referrals, prescriptions (PrEP and other as needed), and notes. Clinicians will also be able to use the portal to track pre-existing medical conditions and concomitant medications, as well as provide referrals for treatment as needed, including sexually transmitted infections (STI), HIV, and others such as mental health or substance use disorders. Finally, the clinical portal will be used by the clinicians to track and monitor the progress of each participant in PrEP care, including the results of SSC kits and scheduling of future consultations. The portal is not currently connected to electronic medical records for each study site, although such functionality could be added later if the trial indicates utility of the intervention.
The primary outcome measure will be protective levels of the active metabolite of oral PrEP (TFV-DP) drug levels at the 12-month study visit, using an intention-to-treat analysis. Using a pharmacological model developed in a cohort study of FTC/TDF use among MSM and transgender women , the concentration of TFV-DP as determined from a DBS can be used to infer the mean number of days per week FTC/TDF is ingested over approximately 1 month preceding specimen collection. The threshold used for the primary outcome measure will be a TFV-DP concentration considered to be a surrogate for substantial HIV protection: >700 fmol/punch, a level indicating ≥4 doses per week [ ]. The intervention efficacy measure will be quantified as the difference in proportions of the intervention arm with this outcome compared with the control arm.
We will assess initiation into PrEP care based on self-report and pill bottle photos. Maintenance in PrEP care at the study midpoint will be assessed with the 6-month TFV-DP drug level measure. We will also track changes in PrEP indication, determined by the CDC and United States Public Health Service guidelines, over the course of each participant’s involvement in the study. Other secondary outcome measures will be harmonized with Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) measures, when possible. Demographic, socioeconomic, and sexual behavioral risk measures are derived from the National HIV Behavioral Surveillance (NHBS) instrument and our previous research instruments [, ]. Adherence will be assessed with self-reported number of pills taken in the past week. Safety outcomes will include acute HIV symptoms assessed with a checklist of 17 symptoms and criteria identified by Braun [ ] and the presence of more common adverse effects identified on the medication label. A number of domains of the study’s theoretical model will be assessed to explore the context of the intervention performance: PrEP perceptions and PrEP use adapted from NHBS and other sources [ , ], depression [ ], illicit and nonprescription drug use [ ], sexual stigma [ ], HIV severity and risk perceptions [ ], HIV knowledge [ ], medication adherence self-efficacy [ ], the Systems Usability Scale [ , ], insurance coverage [ ], use of social and geosocial networking sites [ ], and the depth of clinician-patient relationship [ , ]. We will also seek to understand rationales for those who fail to persist in PrEP, assessing perceptions of PrEP barriers and concerns [ , ].
Power analyses assumed 80% power to detect a difference at a 2-sided 5% significance level, using a 2-sample comparison of proportions. On the basis of retention in our past trials, we assumed a 20% attrition rate in both arms, with calculations assuming independent censoring. If 5% of participants in the control arm are above cut point levels of the outcome measure (TFV-DP), we will have sufficient power to detect a minimum detectable effect size of 13% absolute difference in the outcome measure (eg, ≥18% of the intervention participants have TFV-DP above cut point threshold). To allow for the detection of a scenario where intervention outcome proportion is equal to control+20% absolute increase, our study would remain sufficiently powered with any control participant uptake level ≤15%.
Statistical Analysis Plan
Logistic regression and log-linear models will be used to estimate the association between the intervention arm and primary study outcome, TFV-DP level. If prognostic factors associated with the outcome remain insufficiently balanced through stratified randomization, we may adjust for these factors in our models. Potential confounding factors that may be included are medication self-efficacy and motivation to take PrEP. Per protocol assessments that account for potential changes in intervention as delivered will be conducted. For instance, this would account for participants assigned to the intervention condition opting to instead receive standard of care PrEP from a nonstudy clinician.
A number of secondary analyses will be conducted using regression models. Intervention impact on the secondary outcomes of PrEP initiation and PrEP persistence will be determined using analogous regression models. We will model log10 TFV-DP levels as the outcome variable to potentially detect significant smaller, subclinical, differences in adherence between the intervention and control study arms. An additional analysis will account for the changes in each participant’s PrEP eligibility over time, per CDC guidelines. The primary outcome measure and its intent-to-treat analysis assume daily oral PrEP dosing with FTC/TDF. Medications indicated for PrEP, as well as commonly prescribed PrEP dosing, may change over the course of the study. Informed by new approvals and developments, we will measure self-reported medication use and dosing strategy, and a secondary analysis will be performed to account for the influence of these factors on study outcomes. Specific and aggregate measures of safety will be assessed, including renal function, HIV incidence, and incident bacterial STI.
Exploratory analyses of intervention effectiveness across subgroups and analysis of potential mediators of initiation or persistence in PrEP care across both study arms, such as self-efficacy will also be conducted. Understanding variables associated with success or failure in the intervention will inform future research and potentially guide clinician recommendations or policy regarding bringing remote PrEP care to scale. For participants who seroconvert during the study, levels of TFV-DP, PrEP persistence, and other clinically relevant study data will be analyzed.
Cost-Effectiveness and Cost-Utility Analyses
We will employ standard methods of cost analyses as recommended by the U S Panel on Cost-Effectiveness in Health and Medicine  and as adapted to HIV/AIDS programs [ ]. This will be accomplished by conducting an economic analysis from the payer and societal perspectives to estimate the cost, cost-effectiveness, and cost-utility of the intervention relative to standard of care.
Comprehensive cost analysis will be conducted to assess the cost of developing and implementing the ePrEP intervention, using a microcosting approach to estimate net costs. Cost-effectiveness analyses will include calculating the incremental cost-effectiveness ratio for the cost per HIV infection averted compared with standard of care as follows: (CostIntervention – CostStandardofCare) / (Infections avertedIntervention – Infections avertedStandardofCare). The health effect will be defined as the projected reduction in HIV infections over time associated with adopting the intervention relative to standard of care. The base, standard of care, model will estimate the number of infections expected in the absence of the intervention and may vary under different assumptions of baseline and clinic-based PrEP coverage outside of the intervention . In the cost-utility analysis, we will calculate the cost per quality-adjusted life year (QALY) saved. QALYs saved by averting an HIV infection will be up-to-date estimates from the literature.
In-depth interviews will be conducted after the completion of 12-month assessments with key participants to explore the experience of intervention participants (up to 10) and standard of care participants (up to 5) over time. Participants will be selected using purposive sampling methods, seeking to gain a diverse set of trajectories in PrEP care. Topics will include (1) barriers and facilitators to PrEP care, (2) problems with and benefits of ePrEP or standard of care, (3) ways to address problems and amplify success of ePrEP or standard of care, and (4) factors that influence successful persistence in or falloff from PrEP care.
Safety data will be collected throughout the study for reports of adverse events, social harms, and side effects. Reportable events will be captured through EDC. A safety monitoring committee (SMC) will convene biannually and receive data reports on a quarterly basis. The SMC will be tasked with stopping the study if the intervention proves to be significantly outperforming the standard of care, or if the inverse occurs. We will conduct 1 interim analysis comparing the efficacy of the intervention in the active arm with the control arm, with efficacy based on differences in trial success versus failure using the primary outcome definition (detectable TFV-DP at 12 months). If the intervention is significantly outperforming the standard of care, the study will seek to adjust study design and supplements to open the intervention arm. The SMC will monitor several other factors, including HIV seroconversion, changes in kidney function, behavioral disinhibition, medication adherence, and differential loss to follow-up.
Trial Registration, Ethics, Consent, and Institutional Board Approval
This study has been approved by the University of North Carolina Institutional Review Board (number 18-0107). Clinical trial best practice will be followed in accordance with National Institutes of Health (NIH) guidance. The trial has been registered with ClinicalTrials.gov, trial number NCT03729570. Informed consent will be obtained before any study procedures are initiated.
We anticipate that the study will begin enrolling in May 2019. Our targeted enrollment period is 12 to 18 months. Therefore, we anticipate the completion of study data collection in mid to late 2021 and study results being available in 2022.
PrEP is highly effective in preventing HIV transmission. Similar to the predominant mode of biomedical prevention preceding it (condoms) , the most frequent failure is because of nonuse rather than the failure of the intervention itself [ ]. The challenge for PrEP is therefore how to promote uptake and persistence in care among those groups at highest risk of HIV transmission. The delivery of PrEP services at a distance (and without the need for a provider visit) has the potential to overcome not only the geographic and transit-related barriers to care, but also the reluctance to seek care because of documented barriers to care such as stigma [ ]. Pilot data from other studies indicate a strong interest in home-based PrEP service access [ ] and survey data indicate an overall interest in PrEP [ ]. Yet, there may be some disadvantages of PrEP home care. For instance, individuals may not develop strong bonds with clinicians via video, potentially leading to higher levels of discontinuation than standard care. This clinical trial will allow for the determination of whether telemedicine care increases or decreases initiation of and maintenance on PrEP. Provided that the ePrEP system provides gains relative to standard care, it will be important to develop strategies to sustain the program. The CDC’s high impact HIV prevention program [ ] currently supports several mobile phone apps, and similar investment will be needed to support the coming wave of technology-based interventions such as ePrEP. Cost-effectiveness analyses, such as that proposed for this study, should inform health system investments.
As electronic, mobile phone-based communications emerge to be the predominant form of social interaction among youth , it is only natural that the health care systems reflect this change. The custom PrEP provision platform of the study will allow for an exploration of how youth can be retained in preventive care through an app-based telemedicine system. The recruitment of YMSM, with a focus on black and Latino participation, will provide an important perspective regarding how these highly impacted groups perform in telemedicine care relative to standard care. Provided that the study finds advantages of telemedicine, future work will be needed to understand how to best incorporate such a customized intervention into the broader health care system.
The authors would like to thank all members of the ePrEP and ATN research teams, as well as acknowledge the support and participation of the community in the design of this study.
The research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH, under the ATN protocol 159, U19HD089881. Support was also provided by the National Institute of Mental Health (R01MH114692) and by pilot grant funding from NIH to the Emory Center for AIDS Research (P30AI050409). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Conflicts of Interest
AJS is an investigator on a grant from the Gilead Foundation, which is paid to his institution. He is an investigator on a study for which Gilead Sciences has donated the study drug. CBH is the University of North Carolina site investigator of record for an industry-sponsored clinical trial of PrEP (DISCOVER; NCT02842086), under an interinstitutional contract between the UNC and Gilead Sciences. LAM has received an honorarium from Gilead Science as consultant and member of their Speakers Bureau.
Multimedia Appendix 1
Electronic pre-exposure prophylaxis (ePrEP) study consent form.DOCX File, 103KB
Multimedia Appendix 2
Electronic pre-exposure prophylaxis (ePrEP) study baseline form.DOCX File, 92KB
- Centers for Disease Control and Prevention. 2018. HIV Surveillance Report, 2017 URL: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2017-vol-29.pdf [accessed 2019-05-18] [WebCite Cache]
- Rosenberg ES, Grey JA, Sanchez TH, Sullivan PS. Rates of prevalent HIV infection, prevalent diagnoses, and new diagnoses among men who have sex with men in US states, metropolitan statistical areas, and counties, 2012-2013. JMIR Public Health Surveill 2016 May 17;2(1):e22 [FREE Full text] [CrossRef] [Medline]
- McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016 Jan 2;387(10013):53-60 [FREE Full text] [CrossRef] [Medline]
- Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 Dec 30;363(27):2587-2599 [FREE Full text] [CrossRef] [Medline]
- Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016 Jan;176(1):75-84 [FREE Full text] [CrossRef] [Medline]
- Siegler AJ, Wirtz S, Weber S, Sullivan PS. Developing a web-based geolocated directory of HIV pre-exposure prophylaxis-providing clinics: the prep locator protocol and operating procedures. JMIR Public Health Surveill 2017 Sep 06;3(3):e58 [FREE Full text] [CrossRef] [Medline]
- Siegler AJ, Bratcher A, Weiss KM. PrEP Deserts: Documenting Areas of Limited Geographic Access to PrEP Clinics among Men Who Have Sex with Men in the United States (in press). Am J Public Health 2019.
- Liu AY, Vittinghoff E, von Felten P, Amico KR, Anderson PL, Lester R, et al. Randomized controlled trial of a mobile health intervention to promote retention and adherence to pre-exposure prophylaxis among young people at risk for Human Immunodeficiency Virus: the EPIC study. Clin Infect Dis 2018 Sep 15 Epub ahead of print. [CrossRef] [Medline]
- Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, et al. Randomized controlled trial of daily text messages to support adherence to PrEP in at-risk for HIV individuals: the TAPIR study. Clin Infect Dis 2018 May 02;66(10):1566-1572. [CrossRef] [Medline]
- Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G, National HIV Behavioral Surveillance Study Group. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men US cities, 2014. Clin Infect Dis 2016 Sep 01;63(5):672-677 [FREE Full text] [CrossRef] [Medline]
- US Centers for Disease Control and Prevention. 2018. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update, a Clinical Practice Guideline URL: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf [accessed 2019-05-18] [WebCite Cache]
- Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2 2014 Apr(166):1-73 [FREE Full text] [Medline]
- Zlotorzynska M, Sullivan P, Sanchez T. The annual american men's internet survey of behaviors of men who have sex with men in the United States: 2016 key indicators report. JMIR Public Health Surveill 2019 Feb 20;5(1):e11313. [CrossRef] [Medline]
- Sanchez TH, Sineath RC, Kahle EM, Tregear SJ, Sullivan PS. The annual american men's internet survey of behaviors of men who have sex with men in the United States: protocol and key indicators report 2013. JMIR Public Health Surveill 2015;1(1):e3 [FREE Full text] [CrossRef] [Medline]
- Sanchez TH, Zlotorzynska M, Sineath RC, Kahle E, Tregear S, Sullivan PS. National trends in sexual behavior, substance use and HIV testing among United States men who have sex with men recruited online, 2013 through 2017. AIDS Behav 2018 Aug;22(8):2413-2425. [CrossRef] [Medline]
- Holtzman CW, Shea JA, Glanz K, Jacobs LM, Gross R, Hines J, et al. Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model. AIDS Care 2015;27(7):817-828. [CrossRef] [Medline]
- Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995 Mar;36(1):1-10. [Medline]
- Siegler AJ, Mayer KH, Liu AL, Patel RR, Ahlschlager LM, Kraft CS, et al. Developing and assessing the feasibility of a home-based preexposure prophylaxis monitoring and support program. Clin Infect Dis 2019 Jan 18;68(3):501-504 [FREE Full text] [CrossRef] [Medline]
- Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014 Sep;14(9):820-829. [CrossRef] [Medline]
- Castillo-Mancilla JR, Zheng J, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses 2013 Feb;29(2):384-390. [CrossRef] [Medline]
- Rosenberg ES, Sullivan PS, Dinenno EA, Salazar LF, Sanchez TH. Number of casual male sexual partners and associated factors among men who have sex with men: results from the National HIV Behavioral Surveillance system. BMC Public Health 2011 Mar 25;11:189 [FREE Full text] [CrossRef] [Medline]
- Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Günthard HF. Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. Clin Infect Dis 2015 Sep 15;61(6):1013-1021. [CrossRef] [Medline]
- Jayakumaran JS, Aaron E, Gracely EJ, Schriver E, Szep Z. Knowledge, attitudes, and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS One 2016;11(2):e0145670 [FREE Full text] [CrossRef] [Medline]
- Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009;50(6):613-621. [CrossRef] [Medline]
- Sullivan PS, Peterson J, Rosenberg ES, Kelley CF, Cooper H, Vaughan A, et al. Understanding racial HIV/STI disparities in black and white men who have sex with men: a multilevel approach. PLoS One 2014;9(3):e90514 [FREE Full text] [CrossRef] [Medline]
- Meyer IH, Dean L, Herek GM. Internalized homophobia, intimacy, and sexual behavior among gay and bisexual men. In: Herek GM, editor. Stigma and sexual orientation: Understanding prejudice against lesbians, gay men, and bisexuals. Thousand Oaks: Sage Publications; 1998:160-186.
- van der Snoek EM, de Wit JBF, Götz HM, Mulder PG, Neumann MH, van der Meijden WI. Incidence of sexually transmitted diseases and HIV infection in men who have sex with men related to knowledge, perceived susceptibility, and perceived severity of sexually transmitted diseases and HIV infection: Dutch MSM-Cohort Study. Sex Transm Dis 2006 Mar;33(3):193-198. [CrossRef] [Medline]
- Colbert AM, Sereika SM, Erlen JA. Functional health literacy, medication-taking self-efficacy and adherence to antiretroviral therapy. J Adv Nurs 2013 Feb;69(2):295-304. [CrossRef] [Medline]
- Bangor A, Kortum P, Miller J. An empirical evaluation of the system usability scale. Int J Hum Comput Interact 2008 Jul 30;24(6):574-594. [CrossRef]
- Brooke J. Redhatch Consulting. 1996. SUS-A quick and dirty usability scale URL: https://hell.meiert.org/core/pdf/sus.pdf [accessed 2019-05-25] [WebCite Cache]
- Kealy D, Rice S, Ferlatte O, Ogrodniczuk J, Oliffe J. Better doctor-patient relationships are associated with men choosing more active depression treatment. J Am Board Fam Med 2019;32(1):13-19 [FREE Full text] [CrossRef] [Medline]
- Ridd MJ, Lewis G, Peters TJ, Salisbury C. Patient-doctor depth-of-relationship scale: development and validation. Ann Fam Med 2011 Dec;9(6):538-545 [FREE Full text] [CrossRef] [Medline]
- Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care 2011 Sep;23(9):1136-1145 [FREE Full text] [CrossRef] [Medline]
- Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS 2013 Apr;27(4):248-254 [FREE Full text] [CrossRef] [Medline]
- Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. J Am Med Assoc 2016 Sep 13;316(10):1093-1103. [CrossRef] [Medline]
- Jain KM, Maulsby C, Brantley M, SIF Intervention Team, Kim JJ, Zulliger R, et al. Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs. AIDS Care 2016 Dec;28(9):1199-1204. [CrossRef] [Medline]
- Jenness SM, Goodreau SM, Rosenberg E, Beylerian EN, Hoover KW, Smith DK, et al. Impact of the Centers for Disease Control's HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis 2016 Dec 15;214(12):1800-1807. [CrossRef] [Medline]
- Steiner MJ, Cates W, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis 1999 Sep;26(8):459-462. [Medline]
- Serota DP, Rosenberg ES, Lockard AM, Rolle CM, Luisi N, Cutro S, et al. Beyond the biomedical: PrEP failures in a cohort of young black men who have sex with men in Atlanta, Georgia. Clin Infect Dis 2018 Apr 07. [CrossRef] [Medline]
- Jaiswal J, Griffin M, Singer SN, Greene RE, Acosta IL, Kaudeyr SK, et al. fStructural barriers to pre-exposure prophylaxis use among young sexual minority men: the P18 cohort study. Curr HIV Res 2018;16(3):237-249. [CrossRef] [Medline]
- John SA, Rendina HJ, Grov C, Parsons JT. Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: an opportunity to address barriers to PrEP uptake and persistence. PLoS ONE 2017 Dec 27;12(12):e0189794. [CrossRef] [Medline]
- Purcell DW, McCray E, Mermin J. The shift to high-impact HIV prevention by health departments in the United States. Public Health Rep 2016;131(1):7-10. [CrossRef] [Medline]
- Lenhart A, Smith A, Anderson M, Duggan M, Perrin A. Analysis and Policy Observatory. 2015. Teens, Technology and Friendships URL: https://apo.org.au/node/56457 [accessed 2019-05-26] [WebCite Cache]
|ABMH: Andersen behavioral model adapted to HIV care|
|ATN: Adolescent Medicine Trials Network for HIV/AIDS Interventions|
|CDC: Centers for Disease Control and Prevention|
|DBS: dried blood spot|
|EDC: electronic data capture|
|ePrEP: electronic pre-exposure prophylaxis|
|FDA: Food and Drug Administration|
|HIPAA: Health Insurance Portability and Accountability Act|
|MSM: men who have sex with men|
|NHBS: National HIV Behavioral Surveillance|
|NIH: National Institutes of Health|
|PrEP: pre-exposure prophylaxis|
|QALY: quality-adjusted life year|
|SMC: safety monitoring committee|
|SSC: specimen self-collection|
|STI: sexually transmitted infections|
|TDF: tenofovir disoproxil fumarate|
|TFV-DP: tenofovir diphosphate|
|YMSM: young men who have sex with men|
Edited by G Eysenbach, R Schnall, A Pettifor, B Mustanski, I Holloway, S Allison; submitted 11.03.19; peer-reviewed by J Pintye, V Strotbaum, D Smith; comments to author 28.04.19; revised version received 01.05.19; accepted 02.05.19; published 10.06.19Copyright
©Aaron J Siegler, James B Brock, Christopher B Hurt, Lauren Ahlschlager, Karen Dominguez, Colleen F Kelley, Samuel M Jenness, Gretchen Wilde, Samuel B Jameson, Gina Bailey-Herring, Leandro A Mena. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 10.06.2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.